Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga PSMA 11 and 68Ga RM2 PET/MRI for Biopsy Guidance in Suspected Prostate Cancer
NCT03809078Phase 2Completed
- Sponsor
- Andrei Iagaru
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-DOTA-Bombesin, gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Andrei Iagaru. Started Jan 2019; status: completed.
02
Drugs
68Ga-DOTA-Bombesingallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03809078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809078.